Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01052701 · ClinicalTrials.gov registry record · Phase 1
Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment
A Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01052701: Completed Phase 1 study, sponsored by Johns Hopkins University.
NCT01052701 is a Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01052701, a Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This research is being done to find out whether abacavir (Ziagen®) lowers the levels of ribavirin (Ribapak®) in the body of persons taking these two drugs.
Interventions
- DRUG Ribavirin
- DRUG Ribavirin plus Abacavir (ABC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2009-12 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01052701
The ClinicalTrials.gov registry entry for NCT01052701 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ribavirin is the first listed.
NCT01052701 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01052701 about?
NCT01052701 is a clinical study titled "Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment". This research is being done to find out whether abacavir (Ziagen®) lowers the levels of ribavirin (Ribapak®) in the body of persons taking these two drugs.
What is the current status of trial NCT01052701?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2009-12. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01052701?
The interventions under investigation include: Ribavirin (DRUG), Ribavirin plus Abacavir (ABC) (DRUG).
Who is sponsoring clinical trial NCT01052701?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.